

Summer Edition 2018







Events across Europe

EUROBIOFAIRS COMPASS Each manager, scientist, and business developer has their own individual, specific network — and so, too, their must-attend events vary significantly. Where to meet potential new partners and how to widen one's scope beyond well-known terrain can be quite difficult to determine. Euro Biofairs Compass will help you navigate the European meeting jungle in H2/2018.

Based on advanced partnering and networking tools, Nordic Life Science Days (see p. 40) showcases the best that the Nordic region has to offer. The mix of conference, partnering, and exhibition is hosted in Stockholm (10-12 September).

What biotech has to offer

Starting on 24 September, an entire week will be dedicated to communicating the progress in biotech to the public. The European Biotech Week (see p. 42) is organised by EuropaBio and featured more than 150 events across Europe in its 2017 edition.

Identifying and finding business opportunities - that's what one of the largest biotech events in Europe is about: biospain (25 - 27 September 2018, Seville, p 44). Last year's edition saw more than 750 licencing opportunities for the 800 companies attending.

bioLIVE, a brand-new event, relevant to everyone working in the bioprocessing and manufacturing field, will take place in Madrid (9 - 11 October 2018, Madrid), adjacent to the largest pharma meeting, the CPhI Worldwide. Its ambition: to bring CDMOs and potential customers together (p. 46).

Companies aiming to expand in the Far East are well-advised to attend Asia's largest biotech show, **BioJapan 2018** (10 - 12 October, p. 48) in Yokohama, which will be held together with Regenerative Medicine Japan.

The market-leading annual event in Europe for Industrial Biotechnology and the Bioeconomy, EFIB, will take place this year in Toulouse (16 - 18 October 2018, p. 50). New industrial biotech processes as well as finance will be just few of the topics to be covered - a must-attend.

From 17 - 18 October business development executives from pharma corporations and biotech companies will meet investors at the European partnering conference **EBDC** at in Hanover (p.52). Another partnering must-attend will come to Copenhagen for the first time: From 5 – 7 November the 24th edition of **BIO Europe** (p. 54) will be the place to see and be seen for over 4,000 executives from over 60 countries for highlevel networking, partnering meetings, strategic panel discussions, world-class workshops.

For the sixth year running, Pharma-**Lab** (20 – 21 November 2018, p. 56) calls upon the latest regulatory and scientific developments in all laboratory areas of the pharmaceutical industry. This event, to be held in Düsseldorf, is accompanied by an exhibition, in which suppliers of lab equipment and contract laboratories present their offerings.

More than 1,200 delegates are expected to attend BioFIT 2018 (see p. 58) in Strasbourg, a must-do event for everyone who is interested in partnering, technology transfer, and early licencing (4 – 5 December).

Just turn the page to learn everything you need to know about Europe's must-attend events in the biotech industry.





10-12 September, 2018 Stockholm Waterfront, Stockholm, Sweden

Partnering at its best

SIXTH NORDIC LIFE SCIENCE DAYS NLSDays offers networking and knowledge for anyone interested in the Nordic life sciences, biotechnologies, pharmaceuticals, medical devices, and e-health businesses. The event provides a wealth of opportunities to connect.

Bringing together the best talents in life sciences, offering amazing networking and partnering opportunities, and providing inputs and content on the most recent trends: Nordic Life Science Days attracts leading decision-makers from the life sciences sector, not only from biotech, pharma, and medtech but also from finance, research, policy, and regulatory authorities.

Based on cutting-edge and advanced partnering and networking tools, Nordic

Life Science Days showcases the best that the Nordic region has to offer.

The Nordic way of conducting the life sciences business

The Nordic region is proud to host some of the world's most innovative biotech, medtech, and pharma companies. It also has the twelfth strongest economy, making it the perfect place to invest. Set in the vibrant city of Stockholm, the conference offers super sessions, workshops, company presentations, exhibitions, face-to-face meetings, and unique receptions, providing numerous opportunities to network with peers, potential partners, and investors.

Meetings on your own terms

Every meeting is an opportunity. At NLSDays, we focus on meeting quality, not quantity. We provide ample time for you to meet your fellow delegates in a stress-free environment. NLSDays is a SwedenBIO event produced by Bionordic.

A warm climate

GREETING Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life sciences industry. Since its inception in 2013, the



event has nurtured a community of people from the world of life sciences, and created a unique place to do business. Most attendees express their delight in the informal atmosphere, combined with an organised approach to meeting highly relevant people. Returning visitors come back because they feel they belong to our growing community. For Uli Wendt, a seasoned business developer at French pharma company Sanofi, the event is not to be missed: "NLSDays is a great forum to connect with innovators across the Nordic region, which is an innovation hotspot in metabolism research. I value the informal atmosphere and feel that the conference delivers strong outcomes for the time invested."

We hope to welcome you, too. We create a space for meaningful encounters, with one-on-one meetings being one of the main features of NLSDays. Additionally, the high quality of topics and presenters provide insight into the most recent trends in science and business.

Olivier Duchamp

Director General, NLSDays CEO, Bionordic Services

> QUICK FACTS

Highlights from NLSDays 2017

- > 1,300+ participants
- > 40 countries
- > 17,000+ meeting requests
- > 3,000+ scheduled meetings

Contact

Olivier Duchamp Phone +33 (0)608 804 515 olivier.duchamp@bionordic.com www.nlsdays.com



10-12 sept stockholm waterfront

nordic partnering at its best

a swedenвю event, produced by == bionordic







24-30 September, 2018 All around Europe

Tribute to biotech

EUROPEAN BIOTECH WEEK European Biotech Week calls on the biotech community to start planning events and activities for the week of 24 - 30 September 2018 to make biotech more accessible, understandable, and exciting.

At EuropaBio, the European Association for Bioindustries, we realise how important it is to foster dialogue and information-sharing in the scientifically complex and often misunderstood area of biotechnology. Our members are committed to developing tools to solve some of the world's main challenges, and we have a responsibility to share what we know and facilitate an open discussion among all stakeholders to accompany these developments.

EuropaBio developed the European Biotech Week in 2013 to mark the 60-year anniversary of the discovery of DNA's structure. Each year, together with its member National Associations, EuropaBio promotes the week and provides a platform for all biotech supporters to pool their events and raise awareness about the products and benefits that biotechnology brings in areas as diverse as healthcare, agriculture, food, energy, and industrial processing.

Year upon year, the participation in European Biotech Week has increased, with a record 19 countries taking part in the 2017 edition. The 150+ initiatives organised in the areas of science, education, policy, media, and finance involved thousands of Europeans. Importantly, numerous events were related to jobs and training, including career fairs and hands-on laboratories for adults, students, and children; competitions; open doors in companies, research institutes, and museums; and even theatrical shows.

Collaborate and contribute

EuropaBio strongly encourages all biotech supporters to join forces and participate in whatever way best fits with their mission and resources. To get some inspiration from past events, visit the week's website at www.biotechweek.org or get in contact with us at hello@biotechweek.org.

A proud heritage

GREETING Biotechnology is one of the most exciting fields to be a part of in 2018. Few others enhance quality of life,



knowledge, innovation, productivity, and environmental protection quite like it. Those who are passionate about biotech should speak confidently of its achievements, potential, and challenges. With over 150 events organised last year in 19 countries, we are delighted that the European Biotech Week initiative has become a key part of the biotech calendar that opens the doors to a better understanding of the world we live in. We hope you will join the celebration this year!

The EuropaBio team

> QUICK FACTS

IN 2017

- > 154 events
- > 19 countries
- > 68 media pick-ups across 11 nations

CONTACT

Clément Robijns Communications & Events Officer, EuropaBio C.Robijns@europabio.org

www.biotechweek.org

Get involved in European Biotech Week!

If you are familiar with biotechnology, you know the field provides incredibly innovative solutions for the benefit of mankind despite it often being unknown or misunderstood. That is why the biotech community needs you or your organisation to help raise awareness and make biotech more accessible.

Now in its sixth year, European Biotech Week has offered all supporters of biotechnology the opportunity to host events and develop initiatives that contribute to an increased dialogue and understanding of this amazing technology.

Potential activities are as varied as the supporters themselves, and the organisers of the Week¹ always encourage new ideas and feedback. For inspiration, flip through the magazines of the past editions on www.biotechweek.org.

There are no fees or hidden costs involved.
All organisers can pool their activities on www.biotechweek.org for increased visibility and promotion, and they will later be featured in a widely-distributed post-week magazine. Interested?

Please contact hello@biotechweek.org.

¹EuropaBio – the European Association for Bioindustries – together with its member National Biotech Associations













Part of



biotechweek

f biotechweek

www.biotechweek.org



24-30 September 2018



biospain 2018



25-27 September, 2018 FIBES Exhibition & Congress Centre, Seville (Spain)

Return to Andalusia

BIOSPAIN Spain is an excellent location to attract foreign investors. From the 25th to the 27th of September 2018, the FIBES Exhibition & Congress Centre in Seville (Spain) will be the stage for BIOSPAIN, a forum for all the actors in the biotechnology sector to share knowledge, ideas and experiences.

BIOSPAIN is the largest biotech event organised by a national bioindustry association in Europe. It is organised by ASEBIO, the Spanish Bioindustry Association, and this years' edition is co-organised by the Government of Andalusia. The event hosts twice as many sessions – 35 on average as the rest of the industry events. The sessions are grouped into different sections – partnering, trade fair, confer-

ences and investors' forum. According to a survey carried out after the last edition in 2016, 84.81% of attendees had identified real business opportunities. BIOSPAIN 2016 attracted a diverse group of attendees, from biotechnology companies (47.4%); pharmaceutical companies (10%); investors (5.2%); professionals from the services and consulting sector (10.6%); medical technology companies (2.5%); suppliers and engineering companies (4%) and public / non-profit organizations (20%). The majority of the delegates came from the health sciences sector.

Among the main topics that will be addressed during BIOSPAIN 2018 are: Alzheimer's, Advanced Therapies, agro-food, biobanks, financing programs, the circular economy, artificial intelligence, genetic editing, immunotherapy, resistance to antibiotics, precision medicine and a lot more.

All information about the event can be found online: www.biospain2018.org.

Back to the roots

GREETING We return to Andalusia for the 9th BIOSPAIN edition, ten years after organising BIOSPAIN in Granada. Since then, our evolution as a sector,



and as an event, has gone hand in hand with an upward curve that already places us, on the one hand, as a pole of attraction for international investors, and on the other hand, as the most important partnering event organised entirely by a biotechnology association in Europe and the third largest in the number of companies and b2b meetings.

In this edition, we would like to thank the Junta de Andalusia, the government of Andalusia, for supporting our event, for which we hope to reach, at least, the same participation figures as, or even higher than, those obtained at BIOSPAIN 2016.

BIOSPAIN 2018 will offer a prominent role to the investment forum, taking into account the outstanding level of investors, both national and international, who will attend.

We are expecting you with the hope that you have a successful experience at BIOSPAIN in the beautiful city of Seville!!!!

Jordi Mardí ASEBIO President

> QUICK FACTS

Highlights

- > 800 companies
- > 230 exhibitors
- > 3.000 one-to-one meetings
- > 50 investors
- > 1,750 attendees

Contact

www.biospain2018.org Phone +34 912 109 374 dfernandez@asebio.com

biospain 2018

25th-27th September, 2018 SEVILLE, SPAIN



+750 licensing opportunities

50 investors

1.750 attendees

3.000 one-to-one meetings

233 exhibitors

29 countries represented

49 sessions on the conference program

3rd largest biotech partnering event in Europe



Organized by:



Agency of Innovation and Development of Andalucia IDEA ANDALUSIAN MINISTRY OF EMPLOYMENT, ENTERPRISE AND COMMERCE





















9-11 October, 2018 IFEMA, Madrid, Spain

Biologics at CPhI!

BIOLIVE bioLIVE offers a unique opportunity for any company active in biopharma to put a spotlight on their offering in front of the entire pharma industry. It features excellent science and technology, development, and partnering opportunities through cutting-edge onsite content and matchmaking.

The first-ever edition of bioLIVE – a new event dedicated to bioprocessing and manufacturing – will take place adjacent to CPhI Worldwide in October. This exciting new addition will feature a live content stage, dedicated sessions, and exhibitors from across some of bio's most prominent companies. It's a unique platform connecting biotechs, big pharma, and service providers across the whole value chain in large molecules.

> QUICK FACTS

Highlights

- > 1400 attendees
- > 45+ hours of presentations
- > 30 exhibitors
- > adjacent to CPhI worldwide

Contact

bioLIVE team e-mail: bioLIVEcustomerservice@ ubm.com Phone +31 (0)20 708 1637 To help industry executives look ahead at key trends and developments, bio-LIVE will feature sessions on the industry's hottest issues. The agenda includes topics as diverse as accelerating bio-processing innovation, artificial intelligence in biomanufacturing, and building a skilled bioprocessing workforce to single-use technology innovation and the increased domestic capacity in China.

The event will include an international mix of exhibitors, with industry heavyweights such as Samsung Biologics, and a plethora of high-level speakers. Bringing the small and large molecule worlds together for this first time, bioLIVE creates a vital platform where both industries can learn from each other. The synergies and the exceptional audience of CPhI Worldwide, with 45,000 visitors over three days, will significantly benefit any company involved in the event. "The launch of bioLIVE will help accelerate the development of the bio supply chain, improve knowledge exchange, and create a more collaborative bio/pharma environment," says Eric Langer, President and Managing Partner, BioPlan Associates.

Opposites attract!

GREETINGS The biologics industry is at a crucial stage in its development, as drugs are becoming more complex, volumes are increasing, and pharma is turn-



ing to contract service providers to overcome manufacturing challenges. Initially, biologic developers did production in-house with only activities like fill/finish being handed over to contractors. But now, even novel areas like cell and gene therapies are being outsourced. In addition, emerging biotechs, with little inhouse manufacturing or development capabilities, are now an integral part of the drug pipeline. Complex challenges, development timelines, and the need to lower overall costs industry-wide requires increased access to newer technologies in both upstream and downstream processing.

This complexity means the industry needs an event around which it can centralize its supply chain, and it is why we introduced bioLIVE. In fact, experts from our White Paper suggest that there are a number of cross sector learnings – everything from PAT to supply chain management and even scale-up process improvements. What is most exciting is that we are only just beginning.

Rutger Oudejans Brand Director at UBM

1400












IFEMA MADRID • SPAIN • 9-11 OCTOBER 2018


At The Heart Of Business And Innovation In Biopharma

Evolve faster, successfully deal with challenges and achieve your business goals. Exhibit at bioLIVE, a new focused event with an exhibition and live content stage, bringing the worlds of small and large molecules together.

CPh worldwide

Be a thought leader at the forefront of innovation







10–12 October, 2018 Pacifico Yokohoma, Japan

Partnering in Asia

BIOJAPAN & REGENERATIVE MEDICINE JAPAN This year marks the 20th anniversary of BioJapan, Asia's premier partnering event for the global biotechnology industry. Over 1,000 organisations from industry and academia around the world are expected to take part in this year's partnering, for over 9,000 discussions in total.

Interest in pursuing partnerships with European organisations is on the rise at BioJapan, and accordingly, the presence of national and regional European delegations is more and more apparent. European organisations made up just short of a quarter of participants in last year's partnering event, and the high number of expected returnees in 2018 stands testament to their success.

Besides the partnering and exhibition, the three days of the event (October 10-12) will host a jam-packed seminar and presentation track, including both Japanese and English sessions from pharma, academia, biotechs, ventures, and other organisations. The full schedule will be available online in the coming weeks, and we anticipate new sessions will continue to be announced right up to the start of the event.

Along with the 20th edition of the longstanding Bio Japan, October will also see the return of Regenerative Medicine Japan, a concurrently held exhibition now in its third year. Thanks to recent legislative changes in Japan, the country now boasts a unique environment for the development of regenerative medicine products, with a new conditional approval stage allowing for a time to market of only a couple of years. Accordingly, great growth in the sector is expected in Japan, making the exhibition an exciting prospect for those interested in exploring new opportunities.

The partnering and exhibition spaces are entirely shared between the twinned events, with a full participation cost of aprox. €600 per account.

Asian Prospects

GREETING The increasing number of European participants at BioJapan in recent years is an encouraging sign of the increasing internationalisation of



the Japanese biotechnology industry. We've felt a lot more interest among Japanese organisations in working with teams from overseas, and the number of returning companies and associations from overseas tells us that interest is mutual! We are expecting an even larger international delegation than ever, both in the exhibition and in the partnering.

What's more, with the 2020 Tokyo Olympics now only two years away, the country is doubling down on its efforts to develop a more international-facing infrastructure, so now is the perfect time to visit and build relationships with Japanese companies.

2018 is a special year for BioJapan, as this October we'll be celebrating the exhibition's 20th anniversary. We hope you'll join us in Yokohama to celebrate with us! We look forward welcoming old and new friends to Japan to make this year's event even more successful than ever.

> QUICK FACTS

Contact

biojapan@jtbcom.co.jp Phone: (+81) 3 5657 0758 www.ics-expo.jp/biojapan

Partnering

Opening in July at a cost of 70,000 JPY per account (approximately EUR600)

Sakayu Shimizu

Chairman BioJapan Organizing Committee

Asia's Premier Partnering Event





Partnering

1,500 Participants

35 Countries

10,000 Meetings

Networking Parties



800 Exhibitors

30 Countries

15,000 Visitors



Oct. 10 \(\sim \) \(\sim \) 12 \(\frac{\pi}{2} \)

Pacifico Yokohama, Japan \(\frac{\pi}{2} \)



Organizers:
BioJapan: BioJapan Organizing Committee | JTB Communication Design
Regenerative Medicine Japan: Forum for Innovative Regenerative Medicine (FIRM) | Japan Bioindustry Association (JBA) | JTB Communication Design





16–18 October, 2018 Toulouse, France

Meeting the SDGs

EFIB 2018 About 600 attendees are expected to join the 11th edition of the "European Forum for Industrial Biotechnology and the Bioeconomy" in Toulouse, France. The two-day event will showcase how bio-based solutions help to meet the UN Sustainable Development Goals (SDGs). The START-UP VILLAGE@EFIB initiative welcomes founders in the exhibition.

Companies focusing on industrial biotechnology and bioeconomy are contributing towards achieving 11 out of 17 SDGs, enabling smarter, more efficient use of precious natural resources, developing renewable alternatives to traditional fossil-carbon products, helping to mitigate the impacts of climate change, reducing energy consumption and manmade emissions to soil, air, and water. These are the main results of a new

EuropaBio report about the impact of industrial biotech towards meeting global challenges. "It is critical for Europe to develop a more competitive and sustainable bioeconomy. The EU's 'Horizon Europe' proposal will be key to ensuring that the right investments are made to address societal challenges and deliver on the UN SDGs," said Joanna Dupont-Inglis, EuropaBio Deputy Secretary General. During EFIB 2018 in Toulouse, which is organised

by EuropaBio with the support of BIOCOM AG and Toulouse White Biotechnology (twb), more than 60 international speakers from the industrial biotechnology and bioeconomy arena are expected to highlight the impact of industry-driven innovation to meet the UN SDGs. Presentations in the fields of plastics, nutrition and food, marine biotechnology, synthetic biology, and sustainable aviation, amongst other topics, are planned. Innovations in the areas of processing, packaging, cosmetics, and textiles will be showcased as well. Another session will discuss financial incentives of circular bioeconomy with investors and VCs.

Special invitation to start-ups

For the first time, EFIB offers small and medium-sized companies (SMEs) a reduced fee. Start-ups are invited to take part in the Pitchfest and the START-UP VILLAGE@EFIB.

Grand challenges

GREETING In the last decade, EFIB delegates, exhibitors, sponsors and speakers have been showcasing innovative prod-



ucts and processes that deliver solutions to the UN Sustainable Development Goals. This year, we invite you to join us in celebrating the Industrial Biotech community's latest achievements in harnessing the power of innovation to deliver solutions to global grand challenges. Influential brands and industry leaders, as well as start-ups and entrepreneurs will meet in Toulouse, France, with a broad range of stakeholders and policy-makers to discuss the transformative potential of Industrial Biotechnology to create a more sustainable future.

Joanna Dupont-Inglis, EuropaBio Deputy Secretary General

> QUICK FACTS

Highlights

- > 60+ speakers
- > Reduced fee for SMEs and start-ups
- > 1-to-1-Partnering & Exhibition

CONTACT

Clément Robijns Communications & Events Officer, EuropaBio C.Robijns@europabio.org www.efibforum.org Pictures: EuropaBio (left), SergiyN/shutterstock.com (top)









Bridging Innovation

EBDC BIO Deutschland's annual European business development event, the EBDC, will bring together experts from pharma and biotech with investors and other experts. This year's motto is "Bridging Medical Innovation in Europe."

Half of innovation is anchored in external collaboration. The EBDC provides a forum for making contacts and discussing topics and trends relevant to the drug development market. The conference's participants come from a wide range of backgrounds. Business development executives from international pharmaceutical corporations and European biotech companies will meet with representatives from private equity and venture capi-

tal companies. This is an ideal occasion to meet experts from all areas of business development and make contacts that will offer your company significant strategic and operational advantages.

Werner Lanthaler, CEO of Evotec, and Niels Emmerich, VP Global Head of Search and Evaluation AbbVie, will give the keynotes of the conference. The EBDC also offers spotlight talks on unmet medical needs – such as neurologi-

cal diseases – as well as company presentations and pitches from pre-seed start-ups. Topics of our symposia will include: challenges in cell and gene therapy, big data and digitization in drug development and patient care, as well as exits for biotechs – before and after the IPO. EBDC attendees will have great opportunities for partnering and networking. We offer 20 slots for speed meetings and plenty of additional time for conventional meetings. The first conference day will conclude with a network reception and dinner.

The venue, Hanover Congress Center HCC, is centrally located, 15 minutes from Hanover Central Station and 40 minutes from Hanover Airport via ground transportation. This means easy access to a valuable conference and networking experience.

Registration and information under: http://bit.ly/EBDC2018

Meet experts

GREETING Germany is one of the world's leading medical biotech nations and the majority of German bio-



tech SMEs are active in the medical sector. About one-third of those develop new drugs. In 2016, the estimated total gross added value in the sector of medi-

cal biotechnology was 8.8 bn Euro and Germany's biotech sector continues to grow. This year's EBDC will take place in the German state of Lower Saxony. The state's strengths include a strong research community and an innovative entrepreneurial environment. I would like to personally encourage you to attend the EBDC and partner with our innovative German biotech companies.

Dr. Peter HeinrichChairman of Board
BIO Deutschland

> QUICK FACTS

Registration

http://bit.ly/EBDC2018

Highlights

- > 150 attendees
- > 20 slots for speed meetings
- > Spotlight talks and presentations
- > Start-up pitches

Contact

event@biodeutschland.org



Bridging Medical Innovation in Europe

EBDC 2018 at a glance:

- High class with familiar atmosphere:
 150 attendees
- Perfect platform to liaise with Central Europe's biotech industry
- Sophisticated line-up of speakers
- Main sessions on gene & cell therapy, exits for biotech, brexit impact and big data & digitization
- 20 slots for speedmeetings and lots of time for conventional meetings
- Spotlight talks on unmet medical needs
- Presentations of R&D companies
- Pitches of pre-seed start-ups
- Networking Reception & Dinner





European Business Development Conference

17 to 18 October 2018

Hanover, Germany

Organizer:

BÎO DEUTSCHLAND

Biotechnologie-Industrie-Organisation Deutschland e.V.

Platinum-Sponsor:



Gold-Sponsors:





Conference Supporter:





BIO-EUROPE®

5-7 November, 2018 Bella Center Copenhagen, Copenhagen, Denmark

Unchartered waters

BIO-EUROPE 2018 The 24th annual international partnering conference BIO-Europe® will be held in Copenhagen, Denmark. Europe's largest life sciences partnering conference offers powerful opportunities to network with the right partners across the biotech value chain.

The 24th annual international partnering conference BIO-Europe will be held for the first time in Copenhagen, Denmark. The event offers countless opportunities to network with the right partners among over 4,000 executives from over 60 countries and brings together hundreds of the world's most innovative leaders across the biotech value chain for high-level networking, prescheduled partnering meetings, strategic panel discussions, world-class workshops

and more. The event is also highly regarded for the variety and high calibre of presenting companies, ranging from biotech startups and academic innovators to next-generation, midsize pharma and biotech companies that will bring their innovative technologies, therapies, and solutions to the event with the goal of securing development and commercialisation partners.

If the partnering can be considered the engine, the presenting companies are the fuel that drives the event. BIO-Europe also features a diverse list of industry leaders speaking on workshops and panels. Leading pharmaceutical companies, including all of the big names in pharma, sponsor the event, sending teams of scouts to engage around new and innovative products. Informal networking events in stunning local venues lend further dealmaking opportunities. The 2017 event boasted a major increase across the board, with an all-time record of 4,007 attendees, 24,199 scheduled one-to-one meetings, and 5,142 licensing opportunities posted from among 2,199 companies that attended from 61 countries.

Must-attend

GREETING There is tangible excitement around the arrival of BIO-Europe every year. This event is a key strategic element for global biotech, pharma, and



investment companies that attend in search of new collaboration partners and deal opportunities.

To add to the anticipation, this year BIO-Europe will be held in Copenhagen, Denmark, for the first time. BIO-Europe is expected to draw a high calibre of companies to this vibrant life sciences hub, not only from Europe but from across the globe, to fuel the insatiable drug development industry.

The event brings a high quality and wide variety of companies to present their licensing opportunities directly to potential partners, resulting in alliances that literally change the world. With over 4,000 attendees last year, this event – which pioneered partnering 24 years ago – continues to stoke the engine that drives the industry's growing demand for transformational breakthroughs.

See you in Copenhagen this November!

> QUICK FACTS

Pre-event course

Do you want to hone your negotiation skills? Go for it on November 2-4, 2018 by attending the course "Advanced Business Development."

Registration discount

The early bird discount is available through August 31, 2018.
Please visit
ebdgroup.knect365.com/bioeurope/

Anna Chrisman

EBD Group & KNect365 Life Sciences Managing Director

Save EUR 200, Early Bird deadline is August 31

24TH ANNUAL INTERNATIONAL PARTNERING CONFERENCE

BIO-EUROPE

NOVEMBER 5-7, 2018 // COPENHAGEN, DENMARK

Photo by Martin Heiberg, Copenhagen Media Center

This "must-attend" event is Europe's largest life science partnering conference. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.

WHAT YOU CAN EXPECT:

4,000+

Attendees

150+

Company presentations

5,000+

Licensing
Opportunities

24,000+

One-to-one meetings

2,000+

Companies

100+

Exhibitors

Find out more: ebdgroup.com/bioeurope

Produced by

In collaboration with







20-21 November, 2018 Crowne Plaza Düsseldorf, Düsseldorf / Neuss, Germany

QC/QA lab challenges

PHARMALAB 2018 PharmaLab focuses on the key questions concerning QC and QA professionals in analytics, bioanalytics, and microbiology. This year, the meeting and exhibition highlights the regulatory challenges and their impact on pharmaceutical and biopharmaceutical quality labs.

In recent months, there have been a number of changes in the relevant authority guides and chapters of the pharmacopoeias in Europe and in the US, as, for example, the draft Annex 1 of the EU GMP Guideline with an increased focus on Quality Risk Management (QRM), a new stand-alone guideline on GMP for ATMP, and new drafts of the USP Packaging Chapters. Additionally, modern analytical and microbiological lab systems are increasingly automated and

computer-based. These developments lead to new challenges – like qualifying such new systems and validating the methods or establishing Laboratory Integrated Management Systems (LIMS). And this, in turn, calls for compliance with the GMP Guide Annex 11, PIC/S Data Management and Integrity Practices, and the latest FDA Data Integrity requirements.

Floodlight on a neglected topic

These issues build the core of six English- and four German-speaking conferences at PharmaLab, which also for the first time will finally wade into an oftenneglected topic whose responsibility lies somewhere between QA, QC, and manufacturing: pest control. Although many national and international regulatory quidelines ask for a conclusive concept of pest control for pharmaceutical and biopharmaceutical manufacturers, they do not provide details on what to do and how to do it. PharmaLab therefore wants to provide the platform for an information exchange and to discuss a structured cooperation of the parties involved.

Forum for lab professionals

GREETING Join us on 20 and 21 November in Düsseldorf/Neuss at the 6th PharmaLab for an information exchange and to discuss the topics in analytics, bioanalytics, and microbiology that keep you busy in the lab. Among other issues, activities related to "low endotoxin recovery" and



the European initiatives to reduce animal experiments in labs (3R strategy), are still a strong focus for biopharma companies, contract labs, and authorities. Both of them will be broadly discussed at PharmaLab.

Almost 60 speakers from authorities, industry, contract labs, and research will share with you current regulatory developments, new methods and practical experience. Also, take advantage of the exhibition, with around 30 exhibitors, to get to know the latest lab technology and services. We look forward to seeing you there.

Dr. Günter Brendelberger Axel Schroeder, Concept Heidelberg, Sandard Operations Directors

> QUICK FACTS

Contact & Registration

www.pharmalab-congress.com

Highlights

- Key speakers from the US, Japan, the UK, Denmark, Italy, the Netherlands, Germany, and others
- Ten conferences and two workshops with over 60 lectures
- Networking opportunities and social events



No matter whether bioassays, chemical analytics or microbiological testing, PharmaLab provides the ideal forum to discuss current trends, developments and applications in the pharmaceutical lab. And for you as a solutions provider the PharmaLab exhibition is thus the right platform to present your latest technologies and services for the modern lab.

Create your own programme out of the following conferences:

Bioanalytics

- Analytical Challenges for Biological Drug Substances and Products
- Anforderungen an ATMP/ Neuartige Therapien*

Analytics

- Computerised Systems in Analytical Laboratories
- QC Compliance Trends in Analytical Laboratories
- Methodenvalidierung bei Wirk- und Hilfsstoffen*
- Optimierung von Laborprozessen*

Microbiology

- Endotoxin and Pyrogen Testing
- Rapid Microbiological Methods and Mycoplasma Testing
- Pest Control from classic trap to digital control
- Mikrobiologische Nährmedien von der Auswahl bis zur Qualifizierung



Media Partner:







4–5 December, 2018 Lille Grand Palais, Lille, France

Sourcing innovations

BIOFIT 2018 In December, BioFIT will gather 1,200 international actors from the life sciences sector. The event aims to foster partnerships between academia and industry, between big companies and start-ups, and to offer a European marketplace for pre-seed, seed, and Series A investment in the field of life sciences.

This year, the plenary session will ask how far and how fast will the early-stage investment market in biotech globalise. Seed investment actors are indeed often perceived as geographically anchored, despite the recent trend among early-stage investors to invest in more diverse geographic areas. Moreover, an entire conference track will be dedicated to identifying the right funding sources for early-stage inno-

vations. New collaborative models between academia and industry will be presented in a comprehensive session of panel discussions that will cover, for instance, the use of artificial intelligence in life sciences which impacts the drug discovery processes at all stages, and may influence the shape of collaborative research. Collaborations between animal health and human health players will also be highlighted. Examples

of the role patient organisations play as new partners in the development of life sciences innovation projects will be discussed. Many initiatives often taken jointly by universities, venture firms, companies, charities, and governments aim to better bridge the gap between a promising academic result and a transferrable asset. A complete track of panel discussions will provide BioFIT's audience with numerous examples of those so-called maturation or pre-seed schemes.

BioFIT also offers the opportunity to detect the most innovative and promising start-ups, R&D projects, and licensing opportunities in order to foster partnerships and business development in the life sciences field. Finally, the event's 7th edition will include many hosted events, like the R&D dating for animal health and innovation, the 5th European Genomic Institute for Diabetes Symposium, and the career-boosting "Would-be CEO Networking Lunch."

Tapping reservoirs

GREETING The life sciences industry is increasingly looking to external sources for early-stage innovations, and resort-



ing to external collaborations with academic institutions and young companies. To facilitate these connections, BioFIT enables one-to-one interactions between academic institutions and technology transfer organisations willing to promote their IP and their research capacities, and industry players willing to tap into the reservoir of innovations and technologies that the academic world and startups can offer. BioFIT also addresses the needs of start-ups to partner with established industry players and with the early-stage investment community.

Etienne Vervaecke

General Commissioner of BioFIT & General Manager of Eurasanté

> QUICK FACTS

Expected 2018 key figures

1,200 delegates
35+ countries represented
35 one-to-one meetings / participant
15 conference sessions
50 oral presentations of start-ups
and licensing opportunities

Registration

Early bird tariff runs until June 30.

80 speakers & 100 exhibitors



The leading European partnering event for early-stage innovations and seed investment in the Life Sciences field

